Erin K. Brenner
Keine laufenden Positionen mehr
Vermögen: - $ am 31.01.2024
Profil
Erin K.
Brenner worked as the Chief Product Development Officer at Pear Therapeutics, Inc. from 2020 to 2023.
Prior to this, Brenner attended Middlebury College for undergraduate studies.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
15.02.2023 | 43 310 ( 0,03% ) | - $ | 31.01.2024 |
Ehemalige bekannte Positionen von Erin K. Brenner
Unternehmen | Position | Ende |
---|---|---|
PEAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2023 |
Ausbildung von Erin K. Brenner
Middlebury College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Pear Therapeutics, Inc.
Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |